Other Trials Review

Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic, progressive and disabling auto-immune disease and afflicts up to three per cent of the population in Western countries. It is a very painful condition which can cause severe disability and ultimately affects a person’s ability to carry out everyday tasks.

GW has completed the world’s first controlled trial of a cannabis-based medicine in treating pain due to rheumatoid arthritis (RA), with very encouraging results. Details of this trial are listed below, together with the associated publication and press release:

GW Sativex Rheumatoid Arthritis Pain Trial

Phase II double-blind, randomised, parallel group study to assess the efficacy, safety and tolerability of Sativex compared with placebo for the treatment of pain and stiffness caused by rheumatoid arthritis. (Blake DR et al. Rheumatology. 2006;45(1):50-2). For GW press release, click here.